Logo image of CUE

CUE BIOPHARMA INC (CUE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CUE - US22978P1066 - Common Stock

0.302 USD
+0.02 (+9.03%)
Last: 1/16/2026, 8:03:22 PM
0.31 USD
+0.01 (+2.65%)
After Hours: 1/16/2026, 8:03:22 PM
Fundamental Rating

2

Taking everything into account, CUE scores 2 out of 10 in our fundamental rating. CUE was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of CUE have multiple concerns. CUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CUE had negative earnings in the past year.
  • In the past year CUE has reported a negative cash flow from operations.
  • CUE had negative earnings in each of the past 5 years.
  • In the past 5 years CUE always reported negative operating cash flow.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of CUE (-119.08%) is worse than 78.68% of its industry peers.
  • With a Return On Equity value of -284.49%, CUE is not doing good in the industry: 72.26% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -119.08%
ROE -284.49%
ROIC N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

  • CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CUE has more shares outstanding
  • CUE has more shares outstanding than it did 5 years ago.
  • CUE has a worse debt/assets ratio than last year.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • CUE has an Altman-Z score of -18.96. This is a bad value and indicates that CUE is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CUE (-18.96) is worse than 81.32% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that CUE is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, CUE is in line with its industry, outperforming 44.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -18.96
ROIC/WACCN/A
WACC9.35%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 1.66 indicates that CUE should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.66, CUE is doing worse than 79.06% of the companies in the same industry.
  • A Quick Ratio of 1.66 indicates that CUE should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.66, CUE is not doing good in the industry: 78.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

  • CUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.45%, which is quite impressive.
  • CUE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.51%.
  • CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.83% yearly.
EPS 1Y (TTM)49.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.82%
Revenue 1Y (TTM)-25.51%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%-35.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.99% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CUE will show a very strong growth in Revenue. The Revenue will grow by 74.48% on average per year.
EPS Next Y44.79%
EPS Next 2Y16.34%
EPS Next 3Y12.78%
EPS Next 5Y31.99%
Revenue Next Year-14.98%
Revenue Next 2Y3.09%
Revenue Next 3Y29.64%
Revenue Next 5Y74.48%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • CUE's earnings are expected to grow with 12.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.34%
EPS Next 3Y12.78%

More info and screens

0

5. Dividend

5.1 Amount

  • CUE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (1/16/2026, 8:03:22 PM)

After market: 0.31 +0.01 (+2.65%)

0.302

+0.02 (+9.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners22.94%
Inst Owner Change0%
Ins Owners0.1%
Ins Owner Change12.61%
Market Cap23.78M
Revenue(TTM)7.10M
Net Income(TTM)-37.68M
Analysts83.33
Price Target5.1 (1588.74%)
Short Float %0.47%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.05%
Min EPS beat(2)25.74%
Max EPS beat(2)36.35%
EPS beat(4)3
Avg EPS beat(4)17.45%
Min EPS beat(4)-9.77%
Max EPS beat(4)36.35%
EPS beat(8)6
Avg EPS beat(8)15.2%
EPS beat(12)9
Avg EPS beat(12)11.47%
EPS beat(16)12
Avg EPS beat(16)12.76%
Revenue beat(2)1
Avg Revenue beat(2)7.51%
Min Revenue beat(2)-7.09%
Max Revenue beat(2)22.12%
Revenue beat(4)1
Avg Revenue beat(4)-15.09%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)22.12%
Revenue beat(8)5
Avg Revenue beat(8)27.04%
Revenue beat(12)8
Avg Revenue beat(12)25.28%
Revenue beat(16)9
Avg Revenue beat(16)14.34%
PT rev (1m)0%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-15.49%
EPS NY rev (3m)1.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)47.32%
Revenue NY rev (1m)-36.3%
Revenue NY rev (3m)8.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.35
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.09
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -119.08%
ROE -284.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.35%
Cap/Sales 2.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -18.96
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)32.79%
Cap/Sales(3y)4.77%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.82%
EPS Next Y44.79%
EPS Next 2Y16.34%
EPS Next 3Y12.78%
EPS Next 5Y31.99%
Revenue 1Y (TTM)-25.51%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%-35.58%
Revenue Next Year-14.98%
Revenue Next 2Y3.09%
Revenue Next 3Y29.64%
Revenue Next 5Y74.48%
EBIT growth 1Y16.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25%
OCF growth 3YN/A
OCF growth 5YN/A

CUE BIOPHARMA INC / CUE FAQ

What is the fundamental rating for CUE stock?

ChartMill assigns a fundamental rating of 2 / 10 to CUE.


Can you provide the valuation status for CUE BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to CUE BIOPHARMA INC (CUE). This can be considered as Overvalued.


What is the profitability of CUE stock?

CUE BIOPHARMA INC (CUE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CUE BIOPHARMA INC?

The Earnings per Share (EPS) of CUE BIOPHARMA INC (CUE) is expected to grow by 44.79% in the next year.